August 12, 2022
Shionogi said on August 10 that its oral COVID-19 treatment ensitrelvir demonstrated high antiviral activity against the Omicron subvariant BA.2.75 in an in vitro setting, with its potency similar to that against other existing variants. BA.2.75, a new sublineage of...read more